ArticleAtherosclerosis2008
Glycated LDL increases monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated chemotaxis.
Article in Atherosclerosis, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 52 citations in OpenAlex.
- From bud to stem: dynamics of hematopoietic stem cells that drive homing and mobilization.Current opinion in hematology · 2026Review
- The Potential Role of Advanced Glycation End Products in the Development of Kidney Disease.Nutrients · 2025Review
- Advanced Glycation End Products (AGEs) and Chronic Kidney Disease: Does the Modern Diet AGE the Kidney?Nutrients · 2022Review
- Modified Lipoproteins Induce Arterial Wall Inflammation During Atherogenesis.Frontiers in cardiovascular medicine · 2022Review
- The role of RAGE in host pathology and crosstalk between RAGE and TLR4 in innate immune signal transduction pathways.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Review
- Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease.International journal of molecular sciences · 2020Review
- Article
- Regulation of Metabolic Disease-Associated Inflammation by Nutrient Sensors.Mediators of inflammation · 2018Review
- A Method for In Vitro Measurement of Oxidized Low-Density Lipoprotein in Blood, Using Its Antibody, Fluorescence-Labeled Heptapeptide and Polyethylene Glycol.Journal of fluorescence · 2017Article
- Statin modulation of monocyte phenotype and function: implications for HIV-1-associated neurocognitive disorders.Journal of neurovirology · 2016Article
- Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes.Atherosclerosis · 2016Article
- Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes.Cytokine · 2012 · on this mapReview
- CD36 in the periphery and brain synergizes in stroke injury in hyperlipidemia.Annals of neurology · 2012Article
- Indocyanine green enables near-infrared fluorescence imaging of lipid-rich, inflamed atherosclerotic plaques.Science translational medicine · 2011Article
- Combination of Medicinal Herbs KIOM-79 Reduces Advanced Glycation End Product Accumulation and the Expression of Inflammatory Factors in the Aorta of Zucker Diabetic Fatty Rats.Evidence-based complementary and alternative medicine : eCAM · 2011Article
- Effect of irreversibly glycated LDL in human vascular smooth muscle cells: lipid loading, oxidative and inflammatory stress.Journal of cellular and molecular medicine · 2010Article
- Association of dietary AGEs with circulating AGEs, glycated LDL, IL-1α and MCP-1 levels in type 2 diabetic patients.European journal of nutrition · 2010Article
- Transcriptome analysis of monocyte-HIV interactions.Retrovirology · 2010Article
- Adiponectin inhibits pro-inflammatory signaling in human macrophages independent of interleukin-10.The Journal of biological chemistry · 2009Article
- The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease.Expert reviews in molecular medicine · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundPrevious reports have suggested that levels of advanced glycation end product-modified LDL (AGE-LDL) increase in patients with diabetes due to elevated plasma glucose. However, understanding of the mechanisms by which AGE-LDL may accelerate atherogenesis remains incomplete. METHODS AND
resultsMicroarray and reverse transcription real-time PCR (RT-PCR) analyses revealed that AGE-LDL significantly increased levels of CC chemokine receptor 2 (CCR2) mRNA in human macrophages compared with LDL, an effect accompanied by increased levels of CCR2 protein. Flow cytometry also showed that AGE-LDL increases CCR2 expression on the cell surface following stimulation (48h) (P<0.05). This effect appeared to depend on the receptor for AGE (RAGE), since an anti-RAGE antibody significantly blocked increased CCR2 mRNA. Functional studies demonstrated that exposure of THP-1 monocytoid cells to AGE-LDL increases chemotaxis mediated by monocyte chemoattractant protein-1 (MCP-1) up to 3-fold compared to LDL treatment (P<0.05).
conclusionsThese data show that AGE-LDL can increase CCR2 expression in macrophages and stimulate the chemotactic response elicited by MCP-1. This novel mechanism may contribute to accelerated atherogenesis in diabetic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.